Replies to post #138978 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Sold some this morning expecting a rehash, but I see subtleties:

The most common adverse event (AE): mild dizziness
§ When pa3ents were first dosed with highest dose
§ Was transient and reversible

I take that to mean that AE being a cause for reducing dose may not be the case.

Supported also by slides 17 to 21 pointing to the differences in therapeutic concentrations and/or their effect is suspected to be genetic.

Best case, analysis is being completed and trial start dependent on thorough understanding of inclusion/exclusion criteria. Still not a proponent of the waiting for FDA etc. theory.

[hokieal]

Thanks. I'm curious to see the opinions on this board of the content. Anything interesting jump out to you? At a high level it all looked familiar to me so back to waiting and holding.

On a less relevant note, every time I see their presentations, I really want to hire a PowerPoint guru for them. I know it's minor, but there are some bad slide designs/graphics in there.